Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Carl Gordon acquired 1,000,000 shares of Scribe Therapeutics stock in a transaction on Monday, July 27th. The stock was acquired at an average price of $15.00 per share, with a total value of $15,000,000.00. Following the purchase, the director directly owned 1,348,825 shares in the company, valued at approximately $20,232,375. This trade represents a 286.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Scribe Therapeutics Stock Performance
Shares of Scribe Therapeutics stock opened at $19.48 on Friday. Scribe Therapeutics Inc. has a 1 year low of $17.31 and a 1 year high of $25.49.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
